Company code: Beihai Gofar Chuanshan Biological Co.Ltd(600538) company abbreviation: Beihai Gofar Chuanshan Biological Co.Ltd(600538) Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 All directors of the company attended the board meeting. 3、 Tianjian Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 4、 Pan Libin, the person in charge of the company, Yin Zhibo, the person in charge of accounting, and Li Binbin, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and integrity of the financial report in the annual report. 5、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
Audited by Tianjian Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the listed company in 2021 was 1048653283 yuan, the accumulated profit available for distribution by investors at the end of 2021 was -42527067998 yuan, and the capital reserve at the end of 2021 was 78488140925 yuan.
According to Article 221 of the articles of association, one of the conditions for cash dividends is "the company will distribute dividends in cash when the company makes profits in the current year and the accumulated undistributed profits are positive." As the accumulated undistributed profit of the company is negative, it does not meet the requirements of cash dividend.
After deliberation and approval at the 16th meeting of the 10th board of directors of the company, the company has formulated the profit distribution plan for 2021 as follows: neither profit distribution nor conversion of capital reserve into share capital in 2021. This plan shall be submitted to the general meeting of shareholders of the company for deliberation. 6、 Risk statement of forward-looking statements □ applicable √ not applicable VII. Whether there is non operational occupation of funds by the controlling shareholders and their related parties VIII. Whether there is external guarantee in violation of the specified decision-making procedures IX. whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the annual report disclosed by the Company No
10、 Major risk tips
During the reporting period, there were no particularly significant risks that had a material impact on the company's operation. The company has elaborated various risks and countermeasures that the company may face in the process of operation in this report. Please refer to the relevant contents of "possible risks" in "section III Management Discussion and analysis". 11、 Others □ applicable √ not applicable
catalogue
Section 1 interpretation four
Section II Company Profile and main financial indicators Section III Management Discussion and Analysis Section 4 corporate governance Section 5 environmental and social responsibility 53 section VI important matters Section VII changes in shares and shareholders Section VIII preferred shares 76 section IX relevant information of bonds 77 section x financial report seventy-seven
The documents for future reference of the financial report with the signatures and seals of the legal representative, the person in charge of accounting work and the person in charge of accounting institution, and the original audit report with the seal of the accounting firm and the signature and seal of the certified public accountant
record
Originals of all company documents and announcements publicly disclosed in newspapers designated by the CSRC during the reporting period
Section I interpretation
1、 In this report, unless the context otherwise requires, the following words have the following meanings:
Interpretation of common words
The company, the company and the listed company refer to Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
company
The reporting period refers to the accounting period from January 1, 2021 to December 31, 2021
The two ticket system refers to the one-time invoice for drugs from the production enterprise to the circulation enterprise, and the one-time invoice for drugs from the circulation enterprise to the medical institution
Guofa pharmaceutical factory refers to the pharmaceutical factory of Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
Beijing culture company refers to Guofa Siyuan (Beijing) Culture Communication Co., Ltd
Shenzhen company refers to Shenzhen Guofa R & D Technology Marketing Co., Ltd
Qinzhou pharmaceutical refers to Qinzhou Pharmaceutical Co., Ltd
Beihai pharmaceutical refers to Beihai Guofa Pharmaceutical Co., Ltd
Traditional Chinese medicine decoction piece factory refers to the traditional Chinese medicine decoction piece factory of Qinzhou Pharmaceutical Co., Ltd
Pesticide company refers to Beihai Guofa marine biological pesticide Co., Ltd
Beijing Xiangya Medical Technology Co., Ltd
Goldman Sachs biotechnology refers to Guangzhou Goldman Sachs Biotechnology Co., Ltd
Goldman Sachs Zhizao refers to Guangzhou Goldman Sachs Zhizao Technology Co., Ltd
Jinghui Diantong refers to Guangzhou Jinghui Diantong investment management enterprise (limited partnership)
Da'an chuanggu refers to Guangzhou Da'an chuanggu Enterprise Management Co., Ltd
Performance commitment parties refer to Kang Xiantong, Jing huidiantong, Wu Peicheng, Xu Xuebin and Zhang Fengxiang
Refers to the profit compensation agreement of Beihai Guofa Marine Biological Industry Co., Ltd. for issuing shares and paying cash to purchase assets, the profit compensation agreement of Beihai Guofa Marine Biological Industry Co., Ltd. and the profit compensation agreement (II) of the company for issuing shares and paying cash to purchase assets Beihai supplementary agreement: profit compensation agreement of haiguofa Marine Biological Industry Co., Ltd. for issuing shares and paying cash to purchase assets (III); profit compensation agreement of Beihai Guofa Marine Biological Industry Co., Ltd. for issuing shares and paying cash to purchase assets (IV)
Guide to Huada win-win No. 1 fund Jinghua win-win No. 1 venture capital enterprise (limited partnership)
Huada win-win No. 2 fund refers to Qingdao Huada win-win No. 2 venture capital fund partnership (limited partnership)
Zhongwei Zhengxin refers to Zhongwei Zhengxin (Beijing) Assets Appraisal Co., Ltd
Tianjian certified public accountants refers to Tianjian Certified Public Accountants (special general partnership)
Guofa group refers to Guangxi Guofa Investment Group Co., Ltd
Guoyuan Securities Company Limited(000728) refers to Guoyuan Securities Company Limited(000728)
CSRC refers to the China Securities Regulatory Commission
Yuan, 10000 yuan and 100 million yuan refer to RMB yuan, 10000 yuan and 100 million yuan
Section II Company Profile and main financial indicators
1、 Company information
Chinese name of the company: Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
Chinese abbreviation of the company Beihai Gofar Chuanshan Biological Co.Ltd(600538)
The foreign language name of the company is Beihai GOFAR Chuanshan biological Co., Ltd
The abbreviation of the company's foreign name is GOFAR stock
Legal representative of the company: Pan libin
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Li Yong, Li Liping
Contact address: No. 3, Beibu Bay Middle Road, Beihai, Guangxi No. 3, Beibu Bay Middle Road, Beihai, Guangxi
Tel: 07793200619
Fax: 07793200618
E-mail [email protected]. [email protected].
3、 Basic information
Registered address of the company: No. 3, Beibu Bay Middle Road, Beihai, Guangxi
In June 2014, the company's office address was changed from "No. 9, Beijing Road, Beihai City, Guangxi Zhuang Autonomous Region" to "No. 8, Beibu Bay Middle Road, Beihai City, Guangxi Zhuang Autonomous Region". For details, see the announcement on changing the office address disclosed by the historical change of the company's registered address on June 28, 2014 (pro 2014042); In September 2014, the number of the company's office address was changed from "No. 8, Beibu Bay Middle Road, Beihai City, Guangxi" to "No. 3, Beibu Bay Middle Road, Beihai City, Guangxi". For details, see the announcement on the change of office address number disclosed on September 30, 2014 (pro 2014059).
Office address: No. 3, Beibu Bay Middle Road, Beihai, Guangxi
The postal code of the company's office address is 536000
Company website http://www.gofar.com.cn.
E-mail [email protected].
4、 Place of information disclosure and preparation the media name and website of the company's annual report the website of the stock exchange where the company discloses the annual report http://www.sse.com.cn.
The company's annual report is prepared at the office of the board of directors of the company
5、 Company stock profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Beihai Gofar Chuanshan Biological Co.Ltd(600538) Beihai Gofar Chuanshan Biological Co.Ltd(600538)
6、 Other relevant information
Name of accountant employed by the company: Tianjian Certified Public Accountants (special general partnership)
Office address of the firm (within China): 6 / F, 128 Xixi Road, Xihu District, Hangzhou, Zhejiang
Name of signature accountant: Zhang enxue, Shi Lei
Minmetals Securities Co., Ltd
During the reporting period, the continuous office address is No. 3165, Binhai Avenue, Haizhu community, Yuehai street, Nanshan District, Shenzhen
Financial supervision responsibilities: Mine Finance Building 2401
Ask Peng Jun and Liu Peng, the signed financial advisers
Name of handler
The period of continuous supervision is from January 1, 2020 to December 31, 2022
7、 Main accounting data and financial indicators in recent three years (I) main accounting data
Unit: yuan currency: RMB
Year on year comparison in 2020
Main accounting data increase or decrease in the same period in 2021 and 2019
Before adjustment (%)
Operating income 424717057512676998335626769983356 58.6525115352523
Attributable to shareholders of listed companies
